Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- S&P 500, Nasdaq slip as investors digest earnings, data
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
October 4, 2016 1:38 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Summit Therapeutics plc (NASDAQ: SMMT) to $30.00 (from $22.00) after the company licensed out European rights to Phase II candidate ezutromid to Sarepta.
Messer commented, "We believe this deal... More
Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)
October 4, 2016 9:31 AM EDTOppenheimer affirms Summit Therapeutics (Nasdaq: SMMT) at Outperform with a price target of $28 following a new deal with Sarepta (Nasdaq: SRPT).
The firm said, Summit and Sarepta announced this morning a license and collaboration agreement... More
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM EDTBaird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).
Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM EDTRBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it removes a potential competitive threat with just $40M for access to competitor's drugs. He also said it makes the Sarepta more attractive as a takeover.
"Buying into this early-stage potential... More
Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
October 4, 2016 8:44 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $76 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company Sarepta and Summit (NASDAQ: SMMT) announced a licensing and collaboration agreement for EU rights to Summit's utrophin modulation programs... More
Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
October 4, 2016 7:02 AM EDTSarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (the licensed territory), to Summits utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy (DMD). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summits utrophin modulator pipeline. Summit retains commercialization rights in all other... More
